All In Biotech

Drug Trial Radar · NCT07529925

A Clinical Trail of Adalimumab in Treating Chinese Children With Severe Plaque Psoriasis

A Multicenter, Open-label Study on the Efficacy and Safety of Adalimumab in Treating Chinese Children With Severe Plaque Psoriasis

Last checked: Nov 20, 2026Latest source record: Apr 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

30

Planned (sponsor's estimate)

Start

May 2026

Primary completion

Apr 2028

Study completion May 2028

Sponsor

Sponsor type
Industry
First posted
Apr 14, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 4 years, up to 17 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a real-world clinical study of adalimumab. The project plans to enrol 30 participants and aims to evaluate the efficacy and safety of adalimumab in Chinese children with plaque psoriasis, with the primary endpoint being the proportion of participants achieving PASI 75 (PASI score reduction ≥75% from baseline) at week 16.

Conditions

  • Severe Plaque Psoriasis in Chinese Children

Interventions

  • Adalimumab Solution for InjectionDrug

    Adalimumab is a fully human anti-tumour necrosis factor-alpha monoclonal antibody that inhibits the downstream inflammatory cascade by blocking Tumor Necrosis Factor-α (TNF-α), a core inflammatory factor in psoriasis. In March 2020, adalimumab was approved in China for the treatment of severe plaque psoriasis in children and adolescents aged four years and older who have not responded well to topical therapies and phototherapy or are unsuitable for such treatments.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Psoriasis Area and Severity Index 75 at week 16Time frame: Week 16

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.